Evofem Biosciences Files 2024 Annual Report Amendment

Ticker: EVFM · Form: 10-K/A · Filed: Mar 28, 2025 · CIK: 1618835

Sentiment: neutral

Topics: amendment, annual-report, pharmaceutical

Related Tickers: EVFM

TL;DR

EVFM filed its 2024 10-K amendment on 3/28/25. Check for updates.

AI Summary

Evofem Biosciences, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, formerly known as Neothetics, Inc., is based in San Diego, CA, and operates in the pharmaceutical preparations sector. This filing was made on March 28, 2025.

Why It Matters

This amendment provides updated financial and operational information for Evofem Biosciences, Inc., which is crucial for investors and stakeholders to assess the company's performance and outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Evofem Biosciences faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 10-K/A filing?

This 10-K/A filing is an amendment to the annual report for the fiscal year ended December 31, 2024, for Evofem Biosciences, Inc.

When was this amendment filed with the SEC?

This amendment was filed on March 28, 2025.

What was Evofem Biosciences, Inc. formerly known as?

Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.

Where is Evofem Biosciences, Inc. located?

Evofem Biosciences, Inc. is located in San Diego, CA.

What is the Standard Industrial Classification code for Evofem Biosciences, Inc.?

The Standard Industrial Classification code for Evofem Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on March 28, 2025 regarding Evofem Biosciences, Inc. (EVFM).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing